.Attribute Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average consequence of 11 months, clients along with metastatic intestinal cysts that obtained biomarker-matched treatments based upon distributing growth DNA profiling presented a higher scientific advantage than those acquiring unmatched treatment.